Quantinno Capital Management LP Has $34.65 Million Stock Holdings in DexCom, Inc. $DXCM

Quantinno Capital Management LP increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 35.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 551,719 shares of the medical device company’s stock after buying an additional 144,722 shares during the period. Quantinno Capital Management LP’s holdings in DexCom were worth $34,648,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Norges Bank bought a new position in DexCom in the 4th quarter valued at about $483,356,000. AQR Capital Management LLC boosted its holdings in shares of DexCom by 597.8% during the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after acquiring an additional 2,658,158 shares during the period. Employees Provident Fund Board acquired a new position in shares of DexCom in the fourth quarter valued at approximately $145,352,000. J. Stern & Co. LLP grew its position in shares of DexCom by 2,114.8% in the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after purchasing an additional 1,529,641 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of DexCom by 271.4% during the first quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock worth $129,699,000 after purchasing an additional 1,509,219 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider directly owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 98,506 shares of company stock worth $7,205,258. Company insiders own 0.28% of the company’s stock.

DexCom Trading Down 0.8%

Shares of DexCom stock opened at $74.54 on Friday. The firm has a market capitalization of $28.76 billion, a PE ratio of 31.85, a price-to-earnings-growth ratio of 1.24 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm’s 50 day moving average is $72.91 and its 200 day moving average is $69.10. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $87.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter in the previous year, the firm posted $0.48 earnings per share. The company’s revenue was up 13.1% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent research reports. UBS Group set a $96.00 price target on DexCom and gave the company a “buy” rating in a research note on Tuesday. Stifel Nicolaus set a $90.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Friday, June 5th. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a report on Friday, May 1st. Finally, Canaccord Genuity Group set a $82.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $84.71.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom reported second-quarter adjusted earnings of $0.70 per share, above the $0.61 analyst consensus and up from $0.48 a year earlier. Revenue increased 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. DexCom Q2 earnings and revenues top estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to $5.2 billion-$5.3 billion, broadly above the roughly $5.2 billion consensus, citing sustained demand for its continuous glucose monitoring systems. DexCom raises annual revenue forecast on strong demand for glucose monitors
• Positive Sentiment: UBS reaffirmed a Buy rating and set a $96 price target, implying substantial upside from recent trading levels. Other analysts have also maintained favorable ratings, with a reported consensus target near $85.40. UBS reaffirms Buy rating
• Neutral Sentiment: The results point to continuing growth in CGM demand, but DexCom trades at a relatively high earnings multiple. Investors may focus on whether the upgraded outlook can justify the valuation following the stock’s rebound.
• Negative Sentiment: Insider Kevin Sayer sold 26,756 shares worth approximately $2.04 million under a pre-arranged Rule 10b5-1 plan. The scheduled transaction reduces his holdings by 7.52%, although it does not necessarily signal a change in the company’s outlook. DexCom insider share sale
• Negative Sentiment: A law firm solicited shareholders regarding potential fiduciary-duty claims involving DexCom insiders. The notice contains no established finding of wrongdoing, but such litigation-related headlines can add short-term uncertainty. DexCom shareholder litigation notice

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.